gamma-aminobutyric acid has been researched along with Cancer of Prostate in 16 studies
gamma-Aminobutyric Acid: The most common inhibitory neurotransmitter in the central nervous system.
gamma-aminobutyric acid : A gamma-amino acid that is butanoic acid with the amino substituent located at C-4.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Via a prospective, double-blind, placebo-controlled clinical trial, men with hot flashes, on a stable androgen deprivation therapy program for prostate cancer, received a placebo or gabapentin at target doses of 300, 600, or 900 mg/day." | 9.14 | A phase III randomized, double-blind, placebo-controlled trial of gabapentin in the management of hot flashes in men (N00CB). ( Atherton, PJ; Barton, DL; Bearden, JD; Dueck, AC; Fitch, TR; Jafar, S; Khoyratty, BS; Knutson, WH; Kottschade, L; Loprinzi, CL; Marsa, GW; Rowland, KM, 2009) |
| "These results support that gabapentin decreases hot flashes, to a moderate degree, in men with androgen ablation-related vasomotor dysfunction." | 9.14 | A phase III randomized, double-blind, placebo-controlled trial of gabapentin in the management of hot flashes in men (N00CB). ( Atherton, PJ; Barton, DL; Bearden, JD; Dueck, AC; Fitch, TR; Jafar, S; Khoyratty, BS; Knutson, WH; Kottschade, L; Loprinzi, CL; Marsa, GW; Rowland, KM, 2009) |
| "To report a case of successful treatment of refractory hot flashes with gabapentin in a patient with prostate cancer who was receiving combination antiandrogen and gonadotropin hormone-releasing hormone (GnRH) analog therapy." | 7.71 | Gabapentin for hot flashes in prostate cancer. ( Jeffery, SM; Pepe, JJ; Popovich, LM; Vitagliano, G, 2002) |
| "The gabapentin was well tolerated in this trial." | 6.74 | A phase III randomized, double-blind, placebo-controlled trial of gabapentin in the management of hot flashes in men (N00CB). ( Atherton, PJ; Barton, DL; Bearden, JD; Dueck, AC; Fitch, TR; Jafar, S; Khoyratty, BS; Knutson, WH; Kottschade, L; Loprinzi, CL; Marsa, GW; Rowland, KM, 2009) |
| "Gabapentin has been shown to markedly reduce the severity, frequency, and duration of these hot flashes." | 5.31 | Gabapentin for hot flashes in prostate cancer. ( Jeffery, SM; Pepe, JJ; Popovich, LM; Vitagliano, G, 2002) |
| "Via a prospective, double-blind, placebo-controlled clinical trial, men with hot flashes, on a stable androgen deprivation therapy program for prostate cancer, received a placebo or gabapentin at target doses of 300, 600, or 900 mg/day." | 5.14 | A phase III randomized, double-blind, placebo-controlled trial of gabapentin in the management of hot flashes in men (N00CB). ( Atherton, PJ; Barton, DL; Bearden, JD; Dueck, AC; Fitch, TR; Jafar, S; Khoyratty, BS; Knutson, WH; Kottschade, L; Loprinzi, CL; Marsa, GW; Rowland, KM, 2009) |
| "These results support that gabapentin decreases hot flashes, to a moderate degree, in men with androgen ablation-related vasomotor dysfunction." | 5.14 | A phase III randomized, double-blind, placebo-controlled trial of gabapentin in the management of hot flashes in men (N00CB). ( Atherton, PJ; Barton, DL; Bearden, JD; Dueck, AC; Fitch, TR; Jafar, S; Khoyratty, BS; Knutson, WH; Kottschade, L; Loprinzi, CL; Marsa, GW; Rowland, KM, 2009) |
| "To report a case of successful treatment of refractory hot flashes with gabapentin in a patient with prostate cancer who was receiving combination antiandrogen and gonadotropin hormone-releasing hormone (GnRH) analog therapy." | 3.71 | Gabapentin for hot flashes in prostate cancer. ( Jeffery, SM; Pepe, JJ; Popovich, LM; Vitagliano, G, 2002) |
| "The gabapentin was well tolerated in this trial." | 2.74 | A phase III randomized, double-blind, placebo-controlled trial of gabapentin in the management of hot flashes in men (N00CB). ( Atherton, PJ; Barton, DL; Bearden, JD; Dueck, AC; Fitch, TR; Jafar, S; Khoyratty, BS; Knutson, WH; Kottschade, L; Loprinzi, CL; Marsa, GW; Rowland, KM, 2009) |
| "The breadth of literature for the treatment of hot flashes is much smaller in men than that in women." | 2.48 | Androgen deprivation therapy-associated vasomotor symptoms. ( Jones, JM; Kohli, M; Loprinzi, CL, 2012) |
| "Women treated for breast cancer and men receiving androgen ablation for prostate cancer experience hot flushes that are more frequent, severe and longer lasting than those experienced by the general menopausal population." | 2.43 | Treatment of hot flushes in breast and prostate cancer. ( Adelson, KB; Hershman, DL; Loprinzi, CL, 2005) |
| "In men with prostate cancer, hot flushes occur after surgical or medical castration." | 2.43 | Treatment of hot flushes in breast and prostate cancer. ( Adelson, KB; Hershman, DL; Loprinzi, CL, 2005) |
| "5 mg/d, are reasonable initial dosages, and if symptoms do not improve within a week or two, the dosage can be doubled." | 2.42 | Management of hot flashes in breast cancer survivors and men with prostate cancer. ( Stearns, V, 2004) |
| "The most effective nonhormonal treatments for hot flashes include agents from the selective serotonin or noradrenergic reuptake inhibitor (SSRI/SNRI) family." | 2.42 | Management of hot flashes in breast cancer survivors and men with prostate cancer. ( Stearns, V, 2004) |
| "Hot flashes are a significant complaint among many breast cancer survivors and many men undergoing androgen deprivation therapy for prostate cancer." | 2.42 | Management of hot flashes in breast cancer survivors and men with prostate cancer. ( Stearns, V, 2004) |
| "The Dunning rat model of prostate cancer was used." | 1.43 | Gabapentin, an Analgesic Used Against Cancer-Associated Neuropathic Pain: Effects on Prostate Cancer Progression in an In Vivo Rat Model. ( Altun, S; Bugan, I; Djamgoz, MB; Karagoz, Z, 2016) |
| " Our data demonstrate that the timing and dosing of antiandrogens are critical to maximizing the antitumor effects of combination therapy." | 1.43 | Androgen receptor antagonists compromise T cell response against prostate cancer leading to early tumor relapse. ( Fu, YX; Guo, Y; Liang, Y; Pu, Y; Xu, M; Yang, K; Yang, X, 2016) |
| "Gabapentin has been shown to markedly reduce the severity, frequency, and duration of these hot flashes." | 1.31 | Gabapentin for hot flashes in prostate cancer. ( Jeffery, SM; Pepe, JJ; Popovich, LM; Vitagliano, G, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (50.00) | 29.6817 |
| 2010's | 8 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Taylor, RA | 1 |
| Watt, MJ | 1 |
| Solorzano, SR | 1 |
| Imaz-Rosshandler, I | 1 |
| Camacho-Arroyo, I | 1 |
| García-Tobilla, P | 1 |
| Morales-Montor, G | 1 |
| Salazar, P | 1 |
| Arena-Ortiz, ML | 1 |
| Rodríguez-Dorantes, M | 1 |
| Wu, W | 1 |
| Yang, Q | 1 |
| Fung, KM | 1 |
| Humphreys, MR | 1 |
| Brame, LS | 1 |
| Cao, A | 1 |
| Fang, YT | 1 |
| Shih, PT | 1 |
| Kropp, BP | 1 |
| Lin, HK | 1 |
| Ippolito, JE | 3 |
| Piwnica-Worms, D | 2 |
| Bugan, I | 1 |
| Karagoz, Z | 1 |
| Altun, S | 1 |
| Djamgoz, MB | 1 |
| Pu, Y | 1 |
| Xu, M | 1 |
| Liang, Y | 1 |
| Yang, K | 1 |
| Guo, Y | 1 |
| Yang, X | 1 |
| Fu, YX | 1 |
| Loprinzi, CL | 3 |
| Dueck, AC | 1 |
| Khoyratty, BS | 1 |
| Barton, DL | 1 |
| Jafar, S | 1 |
| Rowland, KM | 1 |
| Atherton, PJ | 1 |
| Marsa, GW | 1 |
| Knutson, WH | 1 |
| Bearden, JD | 1 |
| Kottschade, L | 1 |
| Fitch, TR | 1 |
| Jones, JM | 1 |
| Kohli, M | 1 |
| Lefkowits, CC | 1 |
| Arnold, RM | 1 |
| Hu, Y | 1 |
| Garabedian, EM | 1 |
| Humphrey, PA | 1 |
| Gordon, JI | 2 |
| Azuma, H | 1 |
| Inamoto, T | 1 |
| Sakamoto, T | 1 |
| Kiyama, S | 1 |
| Ubai, T | 1 |
| Shinohara, Y | 1 |
| Maemura, K | 1 |
| Tsuji, M | 1 |
| Segawa, N | 1 |
| Masuda, H | 1 |
| Takahara, K | 1 |
| Katsuoka, Y | 1 |
| Watanabe, M | 1 |
| Stearns, V | 1 |
| Adelson, KB | 1 |
| Hershman, DL | 1 |
| Merritt, ME | 1 |
| Bäckhed, F | 1 |
| Moulder, KL | 1 |
| Mennerick, S | 1 |
| Manchester, JK | 1 |
| Gammon, ST | 1 |
| Danilov, VV | 1 |
| Borshchenko, SA | 1 |
| Danilova, TI | 1 |
| Medvedeva, IA | 1 |
| Jeffery, SM | 1 |
| Pepe, JJ | 1 |
| Popovich, LM | 1 |
| Vitagliano, G | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase III Randomized, Double-Blind, Placebo-Controlled Trial of Gabapentin in the Management of Hot Flashes in Men[NCT00028574] | Phase 3 | 223 participants (Actual) | Interventional | 2001-12-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for gamma-aminobutyric acid and Cancer of Prostate
| Article | Year |
|---|---|
Androgen deprivation therapy-associated vasomotor symptoms.
Topics: Amines; Androgen Antagonists; Anticonvulsants; Antidepressive Agents; Cyclohexanecarboxylic Acids; F | 2012 |
Management of hot flashes in breast cancer survivors and men with prostate cancer.
Topics: Amines; Anti-Anxiety Agents; Breast Neoplasms; Complementary Therapies; Contraceptives, Oral, Synthe | 2004 |
Treatment of hot flushes in breast and prostate cancer.
Topics: Amines; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cimicifuga; Contraindications; Cyclohexan | 2005 |
1 trial available for gamma-aminobutyric acid and Cancer of Prostate
| Article | Year |
|---|---|
A phase III randomized, double-blind, placebo-controlled trial of gabapentin in the management of hot flashes in men (N00CB).
Topics: Aged; Aged, 80 and over; Amines; Androgen Antagonists; Cyclohexanecarboxylic Acids; Dose-Response Re | 2009 |
12 other studies available for gamma-aminobutyric acid and Cancer of Prostate
| Article | Year |
|---|---|
Unsuspected Protumorigenic Signaling Role for the Oncometabolite GABA in Advanced Prostate Cancer.
Topics: gamma-Aminobutyric Acid; Humans; Male; Phosphorylation; Prostatic Neoplasms; Signal Transduction | 2019 |
GABA promotes gastrin-releasing peptide secretion in NE/NE-like cells: Contribution to prostate cancer progression.
Topics: Adenocarcinoma; Aged; Cohort Studies; Disease Progression; GABA Agents; gamma-Aminobutyric Acid; Gas | 2018 |
Linking γ-aminobutyric acid A receptor to epidermal growth factor receptor pathways activation in human prostate cancer.
Topics: Autocrine Communication; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; GABA Agonists; GABA A | 2014 |
A fluorescence-coupled assay for gamma aminobutyric acid (GABA) reveals metabolic stress-induced modulation of GABA content in neuroendocrine cancer.
Topics: Adenocarcinoma; Atlases as Topic; Carcinoma, Neuroendocrine; Cell Line, Tumor; Enzyme Assays; Fluore | 2014 |
Gabapentin, an Analgesic Used Against Cancer-Associated Neuropathic Pain: Effects on Prostate Cancer Progression in an In Vivo Rat Model.
Topics: Amines; Analgesics; Animals; Carcinogenesis; Cells, Cultured; Cyclohexanecarboxylic Acids; Disease M | 2016 |
Androgen receptor antagonists compromise T cell response against prostate cancer leading to early tumor relapse.
Topics: Androgen Receptor Antagonists; Animals; Cell Line, Tumor; gamma-Aminobutyric Acid; Immunity; Immunot | 2016 |
Hot flashes in palliative care. Part 2 #262.
Topics: Amines; Analgesics; Antineoplastic Agents, Hormonal; Breast Neoplasms; Clonidine; Cyclohexanecarboxy | 2013 |
Molecular characterization of a metastatic neuroendocrine cell cancer arising in the prostates of transgenic mice.
Topics: Animals; Aromatic-L-Amino-Acid Decarboxylases; Basic Helix-Loop-Helix Transcription Factors; Cell Di | 2002 |
Gamma-aminobutyric acid as a promoting factor of cancer metastasis; induction of matrix metalloproteinase production is potentially its underlying mechanism.
Topics: Aged; Aged, 80 and over; Baclofen; Dipeptides; Enzyme Induction; GABA Agonists; GABA-B Receptor Agon | 2003 |
Linkage between cellular communications, energy utilization, and proliferation in metastatic neuroendocrine cancers.
Topics: Animals; Calcium; Cell Communication; Cell Proliferation; Citric Acid Cycle; Energy Metabolism; gamm | 2006 |
[Prospects for differentiated conservative treatment of patients with benign prostatic hyperplasia].
Topics: Adrenergic alpha-Antagonists; Aged; Antioxidants; Drug Combinations; gamma-Aminobutyric Acid; Humans | 2001 |
Gabapentin for hot flashes in prostate cancer.
Topics: Acetates; Aged; Amines; Androgen Antagonists; Cyclohexanecarboxylic Acids; Excitatory Amino Acid Ant | 2002 |